Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding

This article has been updated

Abstract

In order to identify potential markers of renal cancer, the plasma membrane protein content of renal cell carcinoma (RCC)-derived cell lines was annotated using a proteomics process. One unusual protein identified at high levels in A498 and 786-O cells was CD70 (TNFSF7), a type II transmembrane receptor normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types demonstrated strong CD70 staining in RCC tissues. Metastatic tissues from eight of 11 patients with clear cell RCC were positive for CD70 expression. Immunocytochemical analysis demonstrated that binding of an anti-CD70 antibody to CD70 endogenously expressed on the surface of A498 and 786-O cell lines resulted in the rapid internalisation of the antibody–receptor complex. Coincubation of the internalising anti-CD70 antibody with a saporin-conjugated secondary antibody before addition to A498 cells resulted in 50% cell killing. These data indicate that CD70 represents a potential target antigen for toxin-conjugated therapeutic antibody treatment of RCC.

Main

Advanced renal cell carcinoma (RCC) is generally resistant to chemotherapy treatment (Yagoda, 1995; Motzer, 1999), and immunotherapy with interferon-alpha and interleukin-2 (IL-2) as single agents or in combination with the chemotherapeutic agent 5-fluorouracil is currently used as systemic treatment for some cases. Response rates remain low at around 15%, and the toxicity of high-dose IL-2 limits its use (Krown, 1987; Muss, 1998; Kammula, 1998; van Herpen et al, 2000). Targeted therapeutics are relatively new to the oncology field, most acting via the inhibition of mitotic signalling kinases. Therapeutic antibodies have been exploited for their target specificity and low toxicity, and many have already been approved for clinical use, including herceptin (trastuzumab) and erbitux (cetuximab), which target the activities of cell-surface receptors, her2 and EGFR, respectively, in solid tumours. Antibodies can also be used to specifically deliver cytotoxic drugs to tumour cells as immunoconjugates that bind to, and internalise with, highly expressed cell surface antigens. An example of an antigen found to be overexpressed in RCC is carbonic anhydrase IX (CA9), which is the target for the monoclonal antibody (mAb) G250 (Pastorek et al, 1994; Uemura et al, 1999; Grabmaier et al, 2000; Li et al, 2001; Bui et al, 2003). Immunoscintigraphy of RCC patients dosed with iodine-131-labelled G250 demonstrated tumour targeting to metastatic sites (Divgi et al, 1998; Steffens et al, 1999; Kennett, 2003).

The aim of this study was to identify other cell-surface proteins specifically associated with RCC that might be suitable targets for antibody-targeted cytotoxic therapeutics. To compile a list of candidate RCC cell-surface proteins, we used a previously described proteomics approach adapted for breast cancer cell lines (Adam et al, 2003) using plasma membrane preparations from the A498, SW839 and CAKI-2 RCC-derived cell lines. As described previously (Adam et al, 2003), potential targets were analysed further using real-time quantitative RT–PCR and immunohistochemistry to quantify expression in normal tissues and clinical RCC samples. We found CD70, a type II transmembrane cell-surface protein of the tumour necrosis factor (TNF) receptor family (Goodwin et al, 1993; Bowman et al, 1994; Hintzen et al, 1994), to be expressed at high levels in RCC, with expression retained in metastatic RCC tissues. We also show that CD70 is rapidly internalised on binding of an anti-CD70 mAb in RCC-derived cell lines and that this property allows specific killing of the CD70-expressing cells by incubating the primary antibody with a saporin-conjugated secondary antibody. These data demonstrate that CD70 is a selective biomarker for the diagnosis and/or treatment of RCC using cytotoxic immunotherapy.

Materials and methods

Preparation of membrane fractions and mass spectrometry

Membrane fractions from the A498 and SW839 RCC-derived cell lines were prepared from 2 × 108 cells as described previously (Adam et al, 2003). Purified membrane proteins were resolved on a 20 cm 6% Laemlli one-dimensional gel (BioRad, Hemel Hempstead, UK) and 0.5 mm slices were subjected to trypsinolysis and prepared for MALDI-TOF mass spectrometry (Voyager STR, Applied Biosystems, Framingham, MA, USA) as previously described (Adam et al, 2003). Selected peptide masses for CD70 (M+H)=1217.6 and 1142.6 were characterised further by MS/MS using a tandem quadrupole TOF mass spectrometer equipped with a nanospray ion source (Micromass UK Ltd, Manchester, UK). Using the SEQUEST search program (Link et al, 1999), ion fragmentation mass spectra of these peptides were sequenced by γ- and β-ion analysis, and identified by comparison with a FASTA database of public domain proteins constructed of protein entries in the non-redundant database held by the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov) and ExPasy (http://www.expasy.com).

Human tissues and cell lines

A range of normal frozen tissues (brain, breast, kidney, liver, tonsil, lymph nodes, skin and thyroid) and tumour tissues were obtained from the Cellular Pathology Department at the John Radcliffe Hospital, Oxford, UK together with pre-sectioned primary and metastatic RCC tissue from Ardais Corporation, Lexington, MA, USA. Frozen sections of 8 μm were cut for each tissue on a cryostat (Leica Microsystems (UK) Ltd, Milton Keynes, Bucks, UK) and mounted on Snowcoat X-tra glass slides (Surgipath Europe Ltd, Peterborough, UK). Following air-drying for 30 min at room temperature (RT), each section was immersed in 100% acetone for 15 min, air dried and then stored at −20°C until required. The human RCC-derived cell lines SW839 (American Type Culture Collection (ATCC): HTB-49), A498 (ATCC: HTB-44), 786-O (ATCC: CRL-1932) and ACHN (ATCC: CRL-1611) were cultured at 37°C in a humidified atmosphere of 95% air and 5% CO2 in growth media specified by the supplier (ATCC, Manassas, VA, USA). A variety of B-cell malignancy derived cell lines (RAMOS, BL16, BL58, AS283, MUTU-III, K562, U937) were kindly provided by Professor Martin JS Dyer, Department of Haematology, University of Leicester, UK. Human PBMCs were purified from donor blood (from the National Blood Service, Bristol, UK) by diluting 1 : 2 in PBS, layering over a 20 ml ficol solution and spinning at 2500 r.p.m. for 20 min.

Flow cytometry

Harvested cell lines were washed in Dulbecco's Phosphate buffered Salt Solution (DPBS) and resuspended at 1 × 107 cells ml−1. Adherent cells were detached by incubation in 0.5 mM EDTA in PBS. Peripheral blood mononuclear cells (PBMCs) were prepared by Ficoll density centrifugation. An aliquot (100 μl) of cell line or PBMCs was then added to each well of a 96-well plate in triplicate. The cells were pelleted by centrifugation and washed once in ice-cold DPBS. DPBS+5% BSA, containing 1 μg ml−1 of anti-CD70 antibody BU69 (Ancell Corporation, Bayport, MN, USA), was then added to each well (200 μl). For control wells, anti-CD70 antibody was substituted for IgG1 isotype control (Serotec Ltd, Oxford, UK). The cells were then incubated on ice for 60 min then washed three times in cold DPBS and resuspended in DPBS+5%BSA containing 10 μg ml−1 of goat anti-mouse Alexa488 conjugate (Molecular Probes Inc., Eugene, OR, USA). Cells were then incubated for a further 60 min on ice, followed by three washes in DPBS, where the final wash contained propidium iodide (10 μg ml−1). Acquisition of data was performed using a FACScalibur flow cytometer (FL1+FL3) with an MPM modification and all subsequent data analysis was performed using CellQuest Pro Software (Becton-Dickinson).

Immunohistochemistry

Tissue sections were first allowed to warm to RT, then immersed for 10 min in 3% hydrogen peroxide in water to quench endogenous peroxidase activity followed by washing in water and then tris-buffered saline (TBS) pH 7.6. A monoclonal mouse anti-human CD70 antibody, HNE.51 (DakoCytomation, Ely, UK), which has been well characterised for CD70 staining on frozen tissues, was applied to the tissues (2 μg ml−1 in TBS) for 90 min followed by two 5 min washes in TBS. Secondary antibody from the DakoCytomation Envision anti-mouse system (DakoCytomation, Ely, UK) was applied for 30 min followed by two washes in TBS. Detection was achieved by a 5 min incubation in the presence of 3,3′-diaminobenzidine (DAB+) substrate chromogen, which results in a brown-coloured precipitate at the antigen site. Sections were counter-stained in Gills II haematoxylin (Surgipath Ltd, Richmond, IL, USA) and mounted under glass coverslips using aqueous mounting medium (Faramount, DakoCytomation, Ely, UK).

Immunocytochemical analysis of antibody internalisation

Cells were seeded at a density of 5 × 104 cells per chamber of an eight-well chamber slide and incubated as normal (37°C, 5% CO2, supplier-recommended media) for 24 h. The cells were cooled to 4°C for 20 min to minimise membrane turnover and media were removed and the cells washed carefully in cold DPBS. Then 1 μg ml−1 anti-CD70 antibody BU69 (Ancell Corporation, Bayport, MN, USA) and isotype control antibody were prepared in 200 μl cold serum free DMEM/F12 media, added to their respective chambers and incubated at 4°C for 20 min. Cells were washed twice with DPBS and the 0 h samples fixed in 4% paraformaldehyde for 10 min. Warmed media were added to the remaining chambers and the cells incubated at 37°C for 2, 4 and 24 h before fixation. After fixation, the cells were washed twice in DPBS, then blocked/permeabilised for 20 min at RT in 0.1% saponin/5% donkey serum in DPBS. Biotinylated goat anti-mouse IgG diluted 1 : 200 (10 μg ml−1) in 0.1% saponin/5% donkey serum/PBS was then added for 1 h at RT followed by three washes in DPBS. Extravidin-Cy3 (Sigma-Aldrich, Poole, UK) diluted 1 : 500 in 0.1% saponin/5% donkey serum/PBS was added for 30 min followed by three washes in PBS. The cells were then mounted in fluorescence enhancing mounting media (DakoCytomation, Ely, UK) and examined using a Leica Microsystems fluorescence microscope with × 63 oil immersion objective.

Saporin-mediated cell killing assay

Antibodies conjugated to the ribosome-inactivating toxin Saporin (Thorpe et al, 1985) were used to evaluate the ability of CD70 to perform as a therapeutic antibody target. Briefly, A498 cells were harvested and resuspended at 1 × 105 cells ml−1. An aliquot of cells (200 μl) was added to each well of a 96-well tissue culture plate and grown to confluence. Cells were washed with PBS and labelled on ice with anti-CD70 antibody BU69 (Ancell Corporation, Bayport, MN, USA) or control IgG1 primary (Serotec Ltd, Oxford, UK) at a range of concentrations. After 30 min, labelled cells were washed three times with cold PBS. Saporin-conjugated goat anti-mouse antibody, Hum-Zap (Advanced Targeting Systems, San Diego, CA, USA), or control antibody was then added to each well to a final concentration of 5 μg ml−1. After incubation for 24 h, cells and debris were harvested from the plate using trypsin digestion and centrifugation. The recovered cell pellet was then resuspended in 1 ml PBS containing propidium iodide (0.1 μg ml−1 final) and percent cell death in each sample calculated by propidium iodide exclusion analysis using a FACScalibur flow cytometer (Becton-Dickinson, Oxford, UK) equipped with Cellquest Pro software.

Real-time quantitative RT–PCR

Real-time quantitative RT–PCR analysis of gene expression (Morrison et al, 1998) was carried out on first-strand cDNA derived from RNA isolated from samples of normal tissues (Clontech, Palo Alto, CA, USA) and RCC tissues (Ardais Corporation, Lexington MA, USA; Peterborough Tissue Bank, Peterborough, UK). All clinical samples were obtained with informed patient consent and ethical approval. Each PCR reaction contained 10 ng first-strand cDNA (prepared from each mRNA sample using Superscript™ reverse transcriptase, Life Technologies, Carlsbad, CA, USA), SYBR green sequence detection reagents (Applied Biosystems, Foster City, CA, USA) and sense and anti-sense primers. All primer pairs traverse at least one intron and test products have been sequenced to confirm specificity before use in these assays. PCR products from all samples were analysed on agarose gels and positives shown to contain a single PCR product of the size predicted from cDNA. No fragments of the size predicted from genomic DNA were detected in any samples, demonstrating the complete absence of genomic DNA contamination. All reactions were run twice and any samples showing a >10% variation in copy number excluded from the analysis. The CD70 primers used were as follows: F, IndexTermgctgctttggtcccattggtcg (exon 1); R, IndexTermgaggtcctgtgtgattcagctg (exon 2/3 junction; 141 bp product). The CA9 primers used were as follows: F, IndexTermcagtgcctatgagcagttgctg (exon 6); R, IndexTermcttagcactcagcatcactgtc (exon 7; 204 bp product). The PCR conditions used for both sets of primers were one cycle at 50°C for 2 min, one cycle at 95°C for 10 min, and 40 cycles of 95°C for 15 s, 65°C for 1 min. Reaction products were assayed on an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) and the accumulation of PCR product was measured in real time as the increase in SYBR green fluorescence. Data were analysed using the Sequence Detector program v1.6.3 (Applied Biosystems, Foster City, CA, USA). Standard curves relating initial template copy number to fluorescence and amplification cycle were generated using the amplified PCR product as a template, and were used to calculate copy number in each sample. Data were expressed as copy number per nanogram cDNA.

Results

Proteomic discovery of CD70 in RCC-derived cell lines

Purified cell membrane protein preparations were isolated from the A498, SW839 and CAKI-2 RCC-derived cell lines and individually separated by one-dimensional PAGE. Sequential 0.5 mm gel slices containing the proteins were subjected to trypsinolysis, and the resulting peptide fragments analysed by MALDI-TOF and MS/MS (Figure 1). Two ion fragmentation mass spectra from two tryptic peptides of masses 1217.6 and 1142.6 Da, respectively, were identified in gel slices corresponding to a molecular weight 23 kDa from the A498 and SW839 RCC-derived cell lines (Figure 1). Using the SEQUEST algorithm (Link et al, 1999), interpretations of these spectra were searched against a FASTA database of public domain proteins and found to uniquely match two peptide sequences (LYWQGGPALGR and SFLHGPELDK) that unambiguously identify the CD70 antigen (Swiss-Prot accession P32970), a type II transmembrane receptor also known as CD27L or TNF ligand superfamily member 7 (TNFSF7) (Figure 1).

Figure 1
figure1

Proteomic discovery of CD70 in the plasma membrane fraction of A498 and SW839 renal carcinoma-derived cell lines. The plasma membrane fraction of A498 and SW839 cell lines was resolved by one-dimensional PAGE. The proteins contained within 0.5 mm consecutive slices of the gel were subjected to trypsinolysis and analysed by MALDI-TOF mass spectrometry with selected masses characterised further by MS/MS using a quadrupole TOF mass spectrometer equipped with a nanospray ion spray. Using the SEQUEST search program, two uninterpreted ion fragmentation mass spectra representing peptides LYWQGGPALGR and SFLHGPELDK identified from the tryptic peptides isolated from a gel slice taken at around 23 kDa were searched against a FASTA database of public domain proteins and were found to match CD70 (SwissProt accession P32970).

To confirm and determine the relative cell-surface expression levels of CD70 in RCC-derived cell lines, the anti-CD70 mAb BU69 was used in FACS analysis. This antibody was selected for FACS and immunocytochemistry as it gave more consistent results in these analyses. The A498, 786-0, and ACHN RCC cell lines and the immortalised HEK293 ‘normal’ kidney cell line were included for FACS analysis, and, as CD70 expression was first described in activated B and T cells, a panel of cell lines with this derivation was also included in the analysis as were the CD19+ and CD3+ subsets of PBMCs. Results demonstrated that expression of CD70 was highest in the A498, then 786-0 RCC-derived cells (Figure 2). Expression in the ACHN cell line was approximately five-fold lower than on the A498 cell line. Cell-surface expression was also detected on the Raji, BL115, AS283, KHM10B and Mutu-III cell lines that are all derived from B-cell malignancies; however, expression on these cell lines was 2–3-fold less than the A498 and 786-O cells (Figure 2). There was no detectable CD70 expression in the T and myeloid cell lines or donor PBMCs analysed. Immunocytochemical analysis with BU69 antibody demonstrated strong membrane reactivity in A498 cells (Figure 2). Scatchard analysis showed that A498, 786-O and ACHN cell lines endogenously expressed 342 000, 265 000 and 33 000 receptors per cell, respectively. FACS and mRNA analyses were also used to determine whether the RCC cell lines expressing CD70 also expressed CD27, the costimulatory receptor for CD70. No detectable CD27 expression could be seen on any of the RCC cell lines tested (data not shown).

Figure 2
figure2

CD70 protein is expressed at the cell-surface of kidney cancer-derived cell lines. An anti-CD70 mAb was used in the context of FACS analysis to determine relative cell-surface protein levels for A498, 786-0, SW839 and ACHN renal carcinoma cell lines. The immortalised embryonic kidney line HEK293 was included as a ‘normal’ kidney cell line control. In addition, as CD70 expression was first described in B/T cells, a panel of cell lines with this derivation was included. The CD19+ or CD3+ subsets of PBMCs were also analysed to confirm the previously observed absence of binding to these cells. Results demonstrated that expression of CD70 was highest in A498 and 786-0 cells. Immunocytochemical analysis was subsequently used to support the finding that CD70 antibody binds to the surface of A498 cells (inset).

CD70 is expressed in primary and metastatic RCC tissues

Having discovered high levels of cell-surface CD70 expression on a number of RCC-derived cell lines, we sought to investigate CD70 expression in clinical RCC tissues. Immunohistochemistry on frozen tissue sections was used to determine expression of CD70 on a number of different types of malignant tissues including 30 kidney cancer donor tissues. The results of this analysis are shown in Table 1. In total, 90 donor tumour tissues were examined; however, only RCC tissues showed strong staining with the anti-CD70 antibody, with 16 out of 30 (53%) cases showing CD70 immunoreactivity. Of all the other tumour tissues examined, weak staining was observed in two of four cases of lymphoblastic lymphoma, four of six cases of large cell lymphoma and one of nine cases of lung adenocarcinoma (Table 1). Examples of CD70 immunostaining of RCC tissues but not normal kidney are shown in Figure 3.

Table 1 List of frozen human malignant tissues immunostained with a monoclonal anti-CD70 antibody
Figure 3
figure3

Immunohistochemical analysis of CD70 in RCCs. CD70 expression throughout the carcinoma tissues of frozen sections of clear cell RCC (ccRCC) is shown (panels i–iii) relative to an isotype matched control antibody (panel iv). CD70 expression was not seen in normal kidney tissues (panel v). Panels i–v all show images at × 20 magnification. Panel vi shows a higher power (× 40) image of a CD70-positive ccRCC tissue demonstrating the plasma membrane expression of CD70 in the carcinoma cells.

Expression of CD70 was also examined in 11 clear cell RCC (ccRCC) metastatic patient tissues, two of which had matched primary ccRCC tumour tissue for comparison. Eight out of eleven (73%) metastatic tissues showed some CD70 expression, and for the two patients with matched primary and metastatic tissues the intensity of CD70 immunostaining of the primary ccRCC and metastasis was in each case the same. Examples of CD70 immunostaining of metastatic ccRCC tissues are shown in Figure 4, in which patient matched primary and metastatic ccRCC CD70 immunostaining is shown (Figure 4, i and ii).

Figure 4
figure4

Immunohistochemical analysis demonstrating that CD70 expression is retained in metastatic tissues derived from primary ccRCC donors. CD70 expression in a primary ccRCC tissue (panel i) is shown alongside expression in a section of adrenal gland metastasis from the same donor (panel ii). Panels iii and iv show CD70 expression in retroperitoneal region metastasis and lung metastasis respectively from two separate donors with primary ccRCC. Magnification × 20.

CD70 is rapidly internalised on antibody binding to RCC-derived cell lines

To determine whether CD70 is a suitable target for cytotoxic-conjugated antibody therapy, we investigated CD70 internalisation on antibody binding. An anti-CD70 antibody, BU69, which is suitable for flow cytometric applications, was added to live A498 and 786-O cells that had been cooled to minimise membrane turnover. After a 20 min incubation at 4°C, a proportion of the cells were fixed to represent a 0 h time point, and warmed serum was added to the remainder of the cells that were subsequently fixed at 1, 2 and 4 h time points. Evidence of internalisation of the anti-CD70 antibody–receptor complex was visualised immunocytochemically as described in Materials and methods (Figure 5). Results showed that for both A498 and 786-O cells at 0 h, there was clear plasma membrane staining only with the anti-CD70 antibody. However, after 1 h of incubation, there was clear internalisation of the antibody–receptor complex as evidenced by a reduction in the intensity of plasma membrane staining and appearance of antibody-containing vesicles within the cells (Figure 5). Internalisation was even more pronounced at 2 h and after 4 h the antibody had completely internalised.

Figure 5
figure5

Immunocytochemical analysis demonstrating rapid CD70 internalisation on anti-CD70 antibody binding. (A) A498 cells showing anti-CD70 antibody binding to the plasma membrane after incubation at 4°C for 20 min (0 h) followed by clear evidence of internalisation of the antibody (endosomal compartmentalisation) at 1, 2 and 4 h after the addition of growth media at 37°C. (B) 786-O cells showing anti-CD70 antibody membrane staining of the cells at 0 h and internalisation after 4 h incubation.

To investigate the ability of the anti-CD70 antibody–receptor complex to internalise with a toxin and kill RCC cell lines endogenously expressing CD70, we coincubated the anti-CD70 antibody with an anti-mouse secondary antibody that was conjugated to saporin before addition to the A498 cell line for 24 h. This demonstrated that using 10 μg ml−1 primary antibody in the presence of 5 μg ml−1 saporin-conjugated secondary antibody, approximately 45% of the cells were killed by the addition of anti-CD70 antibody (Figure 6). In contrast, all the appropriate control incubations showed approximately 5% cell death. A range of other primary antibody concentrations was used, with significant cell killing (25%) observed with 0.08 μg ml−1, the lowest concentration of primary antibody tested (Figure 6).

Figure 6
figure6

Targeting CD70 on A498 cells with an anti-CD70 mAb and Saporin-conjugated secondary antibody results in specific cell kill. Histograms show the % cell kill following incubation in a range of primary antibody concentrations. High levels of cell death were observed only for cells incubated with anti-CD70 and Saporin-conjugated secondary antibody. Propidium iodide exclusion analysis was used to calculate the % cell kill. Mab=anti-CD70, Mzap=goat anti-mouse Saporin conjugate, ISC=IgG1 isotype control, ConZap=Saporin-conjugated goat IgG, anti=goat anti-mouse IgG. Data shown are representative of three separate experiments.

CD70 exhibits a more restricted normal tissue distribution and higher prevalence of expression in RCC tissues than CA9

CA9 is a known antigen currently being targeted for RCC immunotherapy (Divgi et al, 1998; Steffens et al, 1999; Uemura et al, 1999; Grabmaier et al, 2000; Li et al, 2001; Bui et al, 2003; Kennett, 2003). To compare expression of CD70 with CA9, we performed real-time quantitative RT–PCR analysis on multiple normal tissues and clinical RCC samples (Figure 7). These data showed that there was no detectable CD70 mRNA in any of the 29 normal tissues examined; in the thymus, reported expression of CD70 in the medullary epithelium (Hintzen et al, 1994; Tesselaar et al, 2003) was likely diluted below the limit of detection by the presence in this tissue of other, non-expressing cell types. In contrast, there were high levels of CA9 in the stomach and testis, and to a lesser extent in the small intestine and prostate. In the clinical RCC samples, the overall level and prevalence of CD70 mRNA was greater than that of CA9 (Figure 7).

Figure 7
figure7

Comparison of the mRNA expression levels of CD70 and CA9 in normal and RCC tissues. Real-time quantitative RT–PCR analysis was used to calculate the mRNA copies per ng cDNA of CD70 and CA9 in a range of 29 normal tissues and 14 renal cancers: 1=renal cell carcinoma containing both granular and clear cells; 2=chromophobe adenocarcinoma; 3=RCC having a tubular pattern with slightly oxyphilic cells; 4=unknown kidney cancer; 5=transitional cell carcinoma arising from renal pelvis; 6=unknown kidney cancer; 7=renal cell carcinoma of clear cell type; 8=Wilms tumour; 9–12=clear cell renal carcinoma; two RCC donors with matched adjacent normal tissue (N=normal, T=tumour).

Discussion

Identification of antigens expressed specifically and at high levels on kidney cancer cells is a key step in the development of effective immunotherapies for this poorly treated disease. In this paper, we describe the identification of CD70 using proteomic analysis of the plasma membrane fraction of RCC-derived cell lines. CD70 has a very restricted normal tissue expression but was found to be expressed on 16 of 30 RCC clinical specimens and expression was retained in metastatic tissues from ccRCC. In addition, we have demonstrated that binding of an anti-CD70 antibody to cell lines endogenously expressing CD70 results in the rapid internalisation of the antibody–receptor complex, and can mediate cell killing via a toxic immunoconjugate.

CD70 is a type II transmembrane protein that was originally identified as a member of the TNF receptor superfamily with an expression pattern in normal tissues restricted to germinal centre B cells, stromal cells of the thymic medulla and scattered T cells (Goodwin et al, 1993; Bowman et al, 1994; Hintzen et al, 1994). Subsequent studies have described overexpression of CD70 protein in mantle cell lymphoma samples (Zhu et al, 2002); on chronic lymphocytic leukaemia B cells (Lens et al, 1995; Ranheim et al, 1995); and in the tumour cells of thymic carcinomas (Hishima et al, 2000), undifferentiated nasopharyngeal carcinomas (Agathanggelou et al, 1995), gliomas and meningiomas (Held-Feindt and Mentlein, 2002). Additionally, CD70 overexpression was detected in a multidrug-resistant colonic cell line (SW620-MDR) (Fan et al, 2004), and as an inducible gene in TNF-alpha-stimulated human bronchial–epithelial cell line BEAS-2B (Wolf et al, 2002), and irradiated glioma cell lines (Wischhusen et al, 2002). Our study also identified CD70 expression on B-cell malignancy-derived cell lines using FACS analysis (Figure 2), and on six out of twenty clinical lymphoma specimens by immunostaining (Table 1). Anti-CD70 immunostaining on positive RCC sections was much stronger than that of the lymphomas in our study, and quantitative RT–PCR results also showed an overall higher level of CD70 gene transcription in RCC, indicating that the protein is highly over-expressed.

CD70 is the ligand for CD27; studies of this interaction have shown that CD70 promotes cell survival and expansion of antigen-primed CD8+ T cells, formation of memory T cells and proliferation of B cells (Brown et al, 1995; Hintzen et al, 1995; Borst et al, 2005). CD70 protein, whether expressed on dendritic cells (Hintzen et al, 1995), B cells (Rowley and Al-Shamkhani, 2004), tumour cells (Arens et al, 2001), or introduced as soluble protein (Kelly et al, 2002), promotes the survival and expansion of antigen-primed CD8+ T cells in the mouse, through dose-dependent stimulation of CD27 activity. CD70–CD27 interactions may also have a role in memory T-cell formation, which is reduced by CD70 blockade and enhanced by CD70 overexpression or recombinant protein infusion (Borst et al, 2005). The effect of CD70 on B cells is less understood, although in vitro studies suggest that the CD70–CD27 interaction promotes plasma cell differentiation (Cormary et al, 2004), whereas other experiments have demonstrated CD70-driven B-cell proliferation and immunoglobulin synthesis (Agematsu et al, 1995; Kobata et al, 1995). Effects in humans may be more significant than in mice owing to higher and more consistent expression of CD27 in human B cells.

Our studies showed a high-level expression of CD70 on RCC cells that might be expected to induce a strong immune response against the tumour. Frequent expression of CD70 on RCC was recently also reported by Junker et al (2005). Although RCC is known to be a highly immunogenic tumour, it is also a very aggressive cancer that is clearly able to escape immune surveillance. Many other factors are involved in the generation of an immune response and it has already been shown that CD70-driven CD8+ T-cell expansion is dependent upon priming. The high expression of CD70 observed in RCC may be owing to a partial T-cell induction response, or even simply an incidental result of activation/amplification of a genomic locus.

We also demonstrated that CD70 on RCC cell lines internalises rapidly on specific antibody binding, and that this internalisation can be utilised to transport active cytotoxic molecules into cancer cells. This was corroborated by a recent paper describing an anti-CD70 immunoconjugate of doxorubicin that displayed antibody-mediated toxicity against RCC cell lines (Jeffrey et al, 2006).

The development of effective toxin-conjugated immunotherapies will require target antigens that exhibit a highly restricted expression profile in normal tissues, high expression in primary and metastatic cancer tissues and rapid internalisation of the antigen–antibody–toxin complex. CD70 is an antigen that fulfils all of these criteria, in that it is highly overexpressed in a large proportion of renal carcinomas, whereas normal tissue expression is low and restricted to a subset of peripheral blood lymphocytes, and internalises in response to specific antibody binding.

Accession codes

Accessions

GenBank/EMBL/DDBJ

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  1. Adam PJ, Boyd R, Tyson KL, Fletcher GC, Stamps A, Hudson L, Poyser HR, Redpath N, Griffiths M, Steers G, Harris AL, Patel S, Berry J, Loader JA, Townsend RR, Daviet L, Legrain P, Parekh R, Terrett JA (2003) Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem 278: 6482–6489

    CAS  Article  Google Scholar 

  2. Agathanggelou A, Niedobitek G, Chen R, Nicholls J, Yin W, Young LS (1995) Expression of immune regulatory molecules in Epstein–Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol 147: 1152–1160

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Agematsu K, Kobata T, Yang FC, Nakazawa T, Fukushima K, Kitahara M, Mori T, Sugita K, Morimoto C, Komiyama A (1995) CD27/CD70 interaction directly drives B cell IgG and IgM synthesis. Eur J Immunol 25: 2825–2829

    CAS  Article  Google Scholar 

  4. Arens R, Tesselaar K, Baars PA, van Schijndel GM, Hendriks J, Pals ST, Krimpenfort P, Borst J, van Oers MH, van Lier RA (2001) Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNã-mediated B cell depletion. Immunity 15: 801–812

    CAS  Article  Google Scholar 

  5. Borst J, Hendriks J, Xiao Y (2005) CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 17: 275–281

    CAS  Article  Google Scholar 

  6. Bowman MR, Crimmins MA, Yetz-Aldape J, Kriz R, Kelleher K, Herrmann S (1994) The cloning of CD70 and its identification as the ligand for CD27. J Immunol 152: 1756–1761

    CAS  PubMed  Google Scholar 

  7. Brown GR, Meek K, Nishioka Y, Thiele DL (1995) CD27–CD27 ligand/CD70 interactions enhance alloantigen-induced proliferation and cytolytic activity in CD8+ T lymphocytes. J Immunol 154: 3686–3695

    CAS  PubMed  Google Scholar 

  8. Bui MH, Seligson D, Han KR, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9: 802–811

    CAS  PubMed  Google Scholar 

  9. Cormary C, Gonzalez R, Faye JC, Favre G, Tilkin-Mariame AF (2004) Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules. Cancer Gene Ther 11: 497–507

    CAS  Article  Google Scholar 

  10. Divgi CR, Bander NH, Scott AM, O’Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ (1998) Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4: 2729–2739

    CAS  PubMed  Google Scholar 

  11. Fan CW, Chan CC, Chao CC, Fan HA, Sheu DL, Chan EC (2004) Expression patterns of cell cycle and apoptosis-related genes in a multidrug-resistant human colon carcinoma cell line. Scand J Gastroenterol 39: 464–469

    CAS  Article  Google Scholar 

  12. Goodwin RG, Alderson MR, Smith CA, Armitage RJ, VandenBos T, Jerzy R, Tough TW, Schoenborn MA, Davis-Smith T, Hennen K (1993) Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73: 447–456

    CAS  Article  Google Scholar 

  13. Grabmaier K, Vissers JL, De Weijert MC, Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH, Noessner E, Mulders PA, Merkx G, Figdor CG, Adema GJ, Oosterwijk E (2000) Molecular cloning and immunogenicity or renal cell carcinoma-associated antigen G250. Int J Cancer 85: 865–870

    CAS  Article  Google Scholar 

  14. Held-Feindt J, Mentlein R (2002) CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors. Int J Cancer 98: 352–356

    CAS  Article  Google Scholar 

  15. Hintzen RQ, Lens SM, Koopman G, Pals ST, Spits H, van Lier RA (1994) CD70 represents the human ligand for CD27. Int Immunol 6: 477–480

    CAS  Article  Google Scholar 

  16. Hintzen RQ, Lens SM, Lammers K, Kuiper H, Beckmann MP, van Lier RA (1995) Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol 154: 2612–2623

    CAS  PubMed  Google Scholar 

  17. Hishima T, Fukayama M, Hayashi Y, Fujii T, Ooba T, Funata N, Koike M (2000) CD70 expression in thymic carcinoma. Am J Surg Pathol 24: 742–746

    CAS  Article  Google Scholar 

  18. Jeffrey SC, Nguyen MT, Andreyka JB, Meyer DL, Doronina SO, Senter PD (2006) Dipeptide-based highly potent doxorubicin antibody conjugates. Bioorg Med Chem Lett 16: 358–362

    CAS  Article  Google Scholar 

  19. Junker K, Hindermann W, von Eggeling F, Diegmann J, Haessler K, Schubert J (2005) CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol 173: 2150–2153

    CAS  Article  Google Scholar 

  20. Kammula US (1998) Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83: 797–805

    CAS  Article  Google Scholar 

  21. Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, Smyth MJ (2002) Induction of tumor-specific T cell memory by NK-mediated tumor rejection. Nat Immunol 3: 83–90

    CAS  Article  Google Scholar 

  22. Kennett RH (2003) Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research. Curr Opin Mol Ther 5: 70–75

    CAS  PubMed  Google Scholar 

  23. Kobata T, Jacquot S, Kozlowski S, Agematsu K, Schlossman SF, Morimoto C (1995) CD27–CD70 interactions regulate B-cell activation by T cells. Proc Natl Acad Sci USA 92: 11249–11253

    CAS  Article  Google Scholar 

  24. Krown SE (1987) Interferon treatment of renal cell carcinoma: current status and future prospects. Cancer 59: 647–651

    CAS  Article  Google Scholar 

  25. Lens SM, de Jong R, Hintzen RQ, Koopman G, van Lier RA, van Oers RH (1995) CD27–CD70 interaction: unravelling its implication in normal and neoplastic B-cell growth. Leuk Lymphoma 18: 51–59

    CAS  Article  Google Scholar 

  26. Li G, Passebosc-Faure K, Lambert C, Gentil-Perret A, Blanc F, Oosterwijk E, Mosnier JF, Genin C, Tostain J (2001) The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells. Clin Cancer Res 7: 89–92

    PubMed  Google Scholar 

  27. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, Garvik BM, Yates III JR (1999) Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 17: 676–682

    CAS  Article  Google Scholar 

  28. Morrison TB, Weis JJ, Wittwer CT (1998) Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 24: 954–958

    CAS  Google Scholar 

  29. Motzer RJ (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530–2540

    CAS  Article  Google Scholar 

  30. Muss HB (1998) The role of biological response modifiers in metastatic renal cell carcinoma. Semin Oncol 15: 30–34

    Google Scholar 

  31. Pastorek J, Pastorekov S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, Zat’ovicova M, Liao S, Portetelle D, Stanbridge EJ (1994) Cloning and characterization of MN, a human tumor associated protein with a domain homologous to carbonic anhydrase and a putative helix–loop–helix DNA binding segment. Oncogene 9: 2877–2888

    CAS  Google Scholar 

  32. Ranheim EA, Cantwell MJ, Kipps TJ (1995) Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 85: 3556–3565

    CAS  Google Scholar 

  33. Rowley TF, Al-Shamkhani A (2004) Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo. J Immunol 172: 6039–6046

    CAS  Article  Google Scholar 

  34. Steffens MG, Boerman OC, de Mulder PH, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E (1999) Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 5: 3268–3274

    Google Scholar 

  35. Tesselaar K, Xiao Y, Arens R, van Schijndel GM, Schuurhuis DH, Mebius RE, Borst J, van Lier RA (2003) Expression of murine CD27 ligand CD70 in vitro and in vivo. J Immunol 170: 33–40

    CAS  Article  Google Scholar 

  36. Thorpe PE, Brown AN, Bremner JA, Foxwell BM, Stirpe F (1985) An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. J Natl Cancer Inst 75: 151–159

    CAS  PubMed  Google Scholar 

  37. Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, Oosterwijk E (1999) MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 81: 741–746

    CAS  Article  Google Scholar 

  38. van Herpen CML, Jansen RLH, Kruit WH, Hoekman K, Groenewegen G, Osanto S, De Mulder PH (2000) Immunochemotherapy with interleukin-2, interferon-α and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Br J Cancer 82: 772–776

    CAS  Article  Google Scholar 

  39. Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, Huang H, Schulz JB, Ohgaki H, Aguzzi A, Rammensee HG, Weller M (2002) Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 62: 2592–2599

    CAS  PubMed  Google Scholar 

  40. Wolf K, Schulz C, Riegger GA, Pfeiffer M (2002) Tumour necrosis factor-alpha induced CD70 and interleukin-7R mRNA expression in BEAS-2B cells. Eur Respir J 20: 369–375

    CAS  Article  Google Scholar 

  41. Yagoda A (1995) Chemotherapy for advanced renal cell carcinoma: 1983–1993. Semin Oncol 22: 42–60

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Zhu Y, Hollmen J, Raty R, Aalto Y, Nagy B, Elonen E, Kere J, Mannila H, Franssila K, Knuutila S (2002) Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol 119: 905–915

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to A C Stamps.

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and Permissions

About this article

Cite this article

Adam, P., Terrett, J., Steers, G. et al. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer 95, 298–306 (2006). https://doi.org/10.1038/sj.bjc.6603222

Download citation

Keywords

  • proteomics
  • renal cell carcinoma (RCC)
  • CD70
  • antibody
  • internalisation

Further reading

Search

Quick links